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Stefan Engelhardt, MD, PHD,yz Yassine Sassi, PHDySEE PAGE 2214T he means to regenerate cardiac muscle thathas been lost due to myocardial infarction(MI) or cardiomyopathies continues to be a
central focus of cardiovascular research. A large spec-
trum of methodologies and approaches has been
developed and tested in experimental models, with
an increasing number undergoing testing in clinical
trials (1).
Next to approaches that directly target those cells
remaining after a myocardial insult, the exogenous
delivery of cells to injured myocardium has received
much attention (2). The spectrum of cells experi-
mentally delivered for myocardial regeneration is
immense and includes skeletal myoblasts, various
myocardial cell populations (e.g., cardiospheres,
c-kitþ cells), and cardiac myocytes derived from
pluripotent and induced pluripotent stem cells (1,2).
Many of these approaches share the limitations that
they are complex, technically demanding, and difﬁ-
cult to standardize. The clinical testing is mostly at an
early stage, with considerable safety issues to be
resolved.
In contrast, the isolation and transplantation of
bone marrow–derived mononuclear cells (BMMNCs)
are routine in the clinical setting for several hema-
tologic conditions and have been increasingly applied
for nonhematologic diseases, with a major focus on
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Herz-Kreislauf-Forschung.current trial results is that this therapeutic modality
appears to be largely safe, with efﬁcacy ranging be-
tween modest and absent (3). This notion holds true
also for studies using not unfractionated BMMNCs
but subsets of these cells that express certain markers
like CD34, such as utilized by Joladarashi et al. (4) in
this issue of the Journal. Some researchers regard this
cell population as an equivalent of the much-noticed
endothelial progenitor cells (EPCs). However, there is
no universally accepted deﬁnition of EPCs, and
several more complex sets of markers are in use (5).Mechanistically, a consensus is forming that the
various transplanted BMMNC preparations do not
survive, differentiate, or fuse to an extent that rea-
ches functional relevance but rather seem to act
through paracrine factors (6). Taken together, the
transplantation of BMMNCs appears feasible and safe,
yet an increase in their therapeutic efﬁcacy would be
highly desirable and may even be indispensable for
further clinical development of this therapeutic
modality.
It is against this background that Joladarashi
et al. (4) manipulated the levels of an endogenous
micro-ribonucleic acid (miRNA) as a means to in-
crease the therapeutic efﬁcacy of transplanted
CD34þ cells for cardiac repair. As a starting point for
their study, the investigators sought to identify
miRNAs that are functionally relevant in these cells.
To do so, they treated CD34þ cells with an inﬂam-
matory stimulus (lipopolysaccharide [LPS], an ac-
tivator of innate immune signaling) known to
activate these cells, and found that miR-377 is
downregulated. Transfection of synthetic miR-377
inhibited the proangiogenic proteome that these
cells secrete, making miR-377 a candidate mole-
cule to optimize CD34þ cell–based therapies. A
second interesting observation was the prominent
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2228upregulation of miR-377 in the myocardium of
failing hearts. Angiogenesis may aid revasculariza-
tion of ischemic myocardium, and the researchers
therefore speculated that inhibition of anti-angio-
genic miR-377 in CD34þ cells before transplantation
may enhance their therapeutic effect. Indeed, the
study reported higher capillary densities when
ischemic mice received CD34þ cells pre-treated with
inhibitors against miR-377. Most importantly, mice
treated with miR-377–depleted CD34þ cells showed
an improvement in cardiac function and myocardial
remodeling. The authors conclude that inhibition of
miR-377 is a promising strategy to enhance the
therapeutic efﬁcacy of CD34þ cell transplants in
ischemic cardiac damage.
The present study closely matches a recent study
by Wen et al. (7) that likewise used knockdown of
miR-377 in transplanted cells (mesenchymal stem
cells [MSCs]) to enhance their therapeutic efﬁcacy
upon transplant in a model of MI. Similar to the pre-
sent study, Wen et al. reported remarkable increases
in vascular and capillary densities and functional
protection 4 weeks after MI and concomitant injectioned Mechanism of Action for miR-377 in CD34þ Cells
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377) targets serine/threonine kinase 35 (STK35) and possibly other
arrow-derived mononuclear cells positive for CD34. As a net effect,
release of a proangiogenic secretome, inhibiting angiogenesis and
neration. Therapeutic inhibition of miR-377 enhances the angiogenic
cells. Experimentally veriﬁed mechanisms and changes are depicted
putative mechanisms and changes with dotted lines. Red symbolizes
ith anti–miR-377 treatment.of miR-377–depleted MSCs. Mechanistically, Wen
et al. (7) found that miR-377 directly targets vascular
endothelial growth factor (VEGF) and (at least in vitro)
the antiangiogenic properties of miR-377 are mediated
through repression of VEGF. Thus, although both
groups studied a different cell population, they both
report that miR-377 inhibited the proangiogenic
properties of these cells.
It is natural that a complex experimental setting
such as the transplantation of bone marrow–derived
cells into a model of myocardial ischemia also evokes
a number of questions. Before we can regard miR-377
as a regulator of cardiac regeneration, several issues
need to be addressed (see dotted arrows and symbols
in Figure 1) that mainly refer to the proposed mech-
anism of action.
What is the pathophysiological role of the increase
in miR-377 levels in diseased myocardium? Given the
relatively large increase in miR-377 levels in the
myocardium post-MI and the fact that this occurred
in all cell types studied by Joladarashi et al. (4),
miR-377 also becomes an obvious candidate to control
angiogenic factors such as VEGF from the myocardial
side. If this is the case, inhibition of miR-377 within
the host myocardium may confer therapeutic efﬁcacy
in its own right.
What are the direct target molecules of miR-377 in
CD34þ cells? The researchers identiﬁed a single direct
target, which is serine/threonine kinase 35 (STK35).
Until now, the function of STK35 in biology and dis-
ease has remained largely enigmatic. Whether and
how this kinase regulates the behavior of trans-
planted CD34þ cells is an interesting question that
needs further investigation. At the same time,
miR-377 likely targets a number of alternative mole-
cules shaping the angiogenic proﬁle of these and
possibly other cells.
What are the downstream secreted factors, with
alterations upon depletion of miR-377 that are res-
ponsible for the proangiogenic effect of these engi-
neered cells? Transfection of miR-377 repressed a
number of proangiogenic proteins (VEGF, hepatocyte
growth factor, angiopoietin, and others) and inhibited
antiangiogenic factors (thrombospondin-1, platelet
factor-4, and others), but inhibition of miR-377 yiel-
ded only subtle changes compared with control
treatment conditions. This may be explained by low
levels of miR-377 in the cells investigated yet is sur-
prising in light of the strong proangiogenic effects
observed in vivo. Which of these factors alone or
in combination are ultimately responsible for the
proangiogenic signal elicited from transplanted
miR-377–manipulated CD34þ cells is unresolved
and will require additional studies. From another
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2229perspective, these molecules may likewise represent
therapeutic targets themselves.
What happens on the recipient side (i.e., the
injured myocardium) that beneﬁts from the deple-
tion of miR-377 in the transplanted cells? The in-
vestigators reported an increase in capillary density
in line with angiogenic effects upon inhibition of
miR-377 in human umbilical vein endothelial cells.
Although the latter experiment yielded signiﬁcant
increases in migration and tube formation of these
cells, we can only speculate whether this effect
mirrors what would be seen after the addition of
media from miR-377–depleted CD34þ cells. This
would be important to know because a consensus
has emerged in the ﬁeld that these and similar cells
form at best very few endothelial cells and rather
exert their effects through paracrine signals (5,6).
An alternative mechanism of action may be related
to the very acute phase of cell loss, where the
CD34þ cells were applied and where they may affect
cell loss. This would be in line with the considerable
(yet nonsigniﬁcant) trend toward smaller infarcts
and with what Wen et al. (7) showed for trans-
plantation of miR-377–depleted MSCs in an MI
model of permanent left anterior descending artery
ligation (7).Eventually, a direct comparison of the various
means proposed to enhance the functional capacity of
transplanted cells in well-controlled models is desir-
able, as is the identiﬁcation of the preferred cell type.
Given the overwhelming complexity of the mecha-
nisms involved, a systematic analysis of this kind
would be difﬁcult to conduct, however. What we can
realistically hope for are smaller side-to-side com-
parisons of some of the most efﬁcacious strategies
developed to date that may help to better focus on
those types of cell manipulation that have a realistic
chance to succeed also in clinical trials.
The present study is timely because the ﬁeld is
eagerly awaiting the results of the large phase III
BAMI (Bone Marrow-Derived Mononuclear Cells
on All-Cause Mortality in Myocardial Infarction;
NCT01569178) clinical trial. If this clinical trial turns
out positively, approaches such as the one developed
by Joladarashi et al. (4) will have additional relevance
to the ﬁeld.
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